Q Humması Hastalığının Antijenik Peptidinin Sentezi ve Karakterizasyonu

Q humması gram negatif Coxiella burnetii bakterisinin sebep olduğu tüm Türkiye ve Dünya'da yaygın olarak görülen zoonotik bir hastalıktır ve Q humması hastalığı için aşı geliştirme çalışmaları devam etmektedir. Biyoteknolojik aşılardan peptid aşıları sahip olduğu avantajlar ile ön plana çıkmakta ve son yıllarda yaygın olarak çalışılmaktadır. Bu çalışmada Q humması hastalığına ait m1E41920 peptid epitopu (NH2- Ser - Leu - Thr - Trp - His - Lys - His - Glu - Leu - His - Arg - Lys -COOH) mikrodalga destekli katı faz peptid sentezi yöntemiyle sentezlenmiştir. Bu peptidin saflaştırılması ve karakterizayonu yüksek basınçlı sıvı kromatografisi ve kütle spektrometresi ile yapılmıştır. Bu çalışmadan elde edilen saf peptid polimerik adjuvanlara bağlanarak Q humması hastalığı için yeni nesil sentetik peptid aşısı geliştirilmesinde kullanılacaktır.

Antigenic Peptide Synthesis and Characterization of Q Fever Disease

Q fever is common zoonotic disease in Turkey and all over the world caused by the gram negative Coxiella burnetii bacterium. The studies are ongoing to develop vaccine against for Q fever disease. The biotechnological peptide vaccinations become important because of having many advantages and has been studied widely in recent years. Q fever Disease m1E41920 peptide epitope (NH2‐ Ser ‐ Leu ‐ Thr ‐ Trp ‐ His ‐ Lys ‐ His ‐ Glu ‐ Leu ‐ His ‐ Arg ‐ Lys –COOH) of peptid synthesization integrated by using a microwave supported solid phase peptide synthesis method. The extract and characterization of this peptide were carried out by high pressure liquid chromatography and mass spectometer. The pure peptide obtained from this study will be used in the development of a new generation synthetic peptide vaccine for Q fever disease by binding to polymeric adjuvants.

PDF

___

Derman, S., Kızılbey, K., Mansuroğlu, B., Mustafaeva, Z., 2014. Synthesis and characterization of canine parvovirus (CPV) VP2 W‐ 7L‐20 synthetic peptide for synthetic vaccine. Fresen Environ Bul,l 23(2A), 558‐566.
Derman, S. and Mustafaeva A. Z., 2015.Particle size and zeta potential investigation of synthetic peptide‐protein conjugates. Turkish Journal of Biochemistry, 40(4), 282‐289.
Eroğlu, İ. B. and Kılınç, B. Y., 2011. Bioconjugation of Hepatitis B antigenic peptide with polymeric carriers through various carbodiimide chemistry. Turkish Journal of Biochemistry, 36(3), 222‐229.
Fournier, P. E., Thomas, J. M., Raoult, D., 1998. Diagnosis of Q Fever. J. Clin. Microbiol., 36(7), 1823‐1834.
Gale, P., Kelly, L., Mearns, R., Duggan, J., Snary, L. E., 2015. Q fever through consumption of unpasteurised milk and milk products – a risk profile and exposure assessment. Journal of Applied Microbiology, 118, 1083‐1095.
Giraldés, J. 2003. Design And Synthesis Of Handles For Solid‐Phase Peptide Synthesis And Convergent Peptide Synthesis. Doctoral Dissertation, Louisiana State University and Agricultural and Mechanical College, B.S., University of Puerto Rico, 96.
Guzman, F., Barberis, S., Illanes, A., 2007. Peptide synthesis: chemical or enzymatic. Electronic Journal of Biotechnology, 10(2), 279‐314.
Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H., Murthy, K. A., 2014. Peptide Vaccine: Progress and Challenges. Vaccines, 2, 515‐536. Mansuroglu, B., Derman, S. Kızılbey, K.,
Mustafaeva, A. Z., 2009. Investigation of Protein and Polymer as a Carrier on Immune System. International Journal of Natural and Engineering Sciences, 3(2), 32‐35.
Maurin, M. and Raoult, D., 1999. Q Fever. Clin Microbiol Rev., 12(4), 518‐553.
Moisa, A. A. and Kolesanova, E. F., 2010. Synthetic Peptide Vaccines. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 4(4), 321‐332.
Moisa, A. A. and Kolesanova, E. F., 2012. Synthetic Peptide Vaccines. Insight and Control of Infectious Disease in Global Scenario. P. K. Roy, 201‐228.
Mustafaev, M. 2004. Functionally Biopolymer Systems. Sigma Journal of Engineering and Natural Science, 4, 1‐201.
Mustafaev, M. I. and Mustafaeva, Z., 2002. Novel polypeptide‐comprising biopolymer systems. Technology and Health Care, 10(3), 217‐226.
Özbey, G., Kalender, H., Muz, A., 2009. Q Humması’nın Epidemiyolojisi Ve Teşhisi. Sağlık Bilimleri Dergisi (Journal of Health Sciences), 18(2), 100‐110.
Özdemir, Ö. Z., Karahan, M., Karabulut, E., Mustafaeva, Z. 2010. Characterization of Foot‐and‐ Mouth Disease Virus's Viral Peptides with LC‐ESI‐ MS. Journal of The Chemical Society of Pakistan, 32(4), 531‐536.
Özdemir, Ö. Z. and Mustafaeva A. Z. 2011. Development Of Polyelectrolyte Based Bioconjugates Using With Synthetic Viral Peptides. Sigma Journal of Engineering and Natural Sciences, 29, 65‐89.
Özdemir, Ö. Z., 2008. Developing bioconjugates which based on polyelectrolytes, using synthetic viral peptides. PhD Thesis. Yıldız Teknik Üniversitesi, Fen Bilimleri Enstitüsü, İstanbul, 201.
Peng, Y., Schoenlaub, L., Elliott, A., Mitchell J. W., Zhang, G., 2014. Characterization of a Lipopolysaccharide‐Targeted Monoclonal Antibody and Its Variable Fragments as Candidates for Prophylaxis against the Obligate Intracellular Bacterial Pathogen Coxiella burnetii. Infection and Immunity, 82(11), 4530‐4541.
Peng, Y., Zhang, Y., Mitchell, J. W., Zhang, G., 2012. Development of a Lipopolysaccharide‐Targeted Peptide Mimic Vaccine against Q Fever. The Journal of Immunology, 189, 4909‐4920.
Deliloglu, G. S.I., Mustafaev, M., Mustafaeva, Z., Aynagöz, G., Unver, G., Unal N., Celik, N., 2002. Peparation of synthetic peptide FMD vaccine with newly developed antigen‐ polymere conjugates be used as immonogen and vaccine in veterinary medicine. FAO, UN2002, 41, 349‐357.
Skwarczynski, M. and Toth, I., 2016. Peptide‐based synthetic vaccines. Chem. Sci., 7, 842‐854.
Tuğlu, S. 2012. Biomolecule‐polyelectrolyte conjugates. Yüksek Lisans Tezi. Yıldız Teknik Üniversitesi, Fen Bilimleri Enstitüsü, İstanbul, 201.
Vanier, G. S. 2013. Microwave‐Assisted Solid‐Phase Peptide Synthesis Based on the Fmoc Protecting Group Strategy (CEM). Peptide Synthesis and Applications, Springer: 235‐249.
WHO, 1999. Guidelines for the production and quality control of synthetic peptide vaccines. WHO Technical Report Series, No: 889.
Yang, D., Holt, E. G., Rudolf, P. M., Velders, P. M., Brandt, P. R. M., Kwon, D. E., Kast, W. M., 2001. Peptide Vaccines. New Vaccine Technologies. E. W. R. Texas USA: Eurekah.com
1‐ Kitson, D. S. "Carbon‐14 Labelled ADCs & Peptides." from www.almacgroup.com. (29.09.2016).
2‐ Innovagen's peptide property calculator, http://pepcalc.com/ (29.09.2016)